Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy
Hunter C. Gits(Pediatric Oncology Group), Kenneth W. Merrell(Mayo Clinic), Robert R. McWilliams(Mayo Clinic in Arizona), Amy Tang(University of Southern California), Michelle A. Neben Wittich(Mayo Clinic), Sean P. Cleary(University Health Network), Wen Wee(Roswell Park Comprehensive Cancer Center), Mark J. Truty(Mayo Clinic in Arizona), Terence T. Sio(The University of Texas MD Anderson Cancer Center), William G. Rule(Mayo Clinic in Arizona), William R. Bamlet(Mayo Clinic), William S. Harmsen(Mayo Clinic), Rondell P. Graham(Mayo Clinic in Arizona), Gloria M. Petersen(Mayo Clinic), Thomas C. Smyrk(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), Roman O. Kowalchuk(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), Jonathan B. Ashman(Mayo Clinic in Arizona), Amit Mahipal(Dana-Farber Cancer Institute), Þorvarður R. Hálfdánarson(Mayo Clinic), Dawn Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 8
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Mutation of a <i>mutL</i> Homolog in Hereditary Colon Cancer
|Science|1994|1.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k